A cost-related approach for evaluating drug development programs

09/30/04

Permalink 06:32:59 am, by damageva Email , 176 words, 58 views   English (US)
Categories: Health

A cost-related approach for evaluating drug development programs

Most pharmaceutical statisticians make a contribution to drug development at the study level by designing and analysing clinical studies. There is less involvement at the drug project level, especially when it comes to making a strategic decision for a drug development program. Motivated by the assessment of drug safety, this paper presents a new decision rule on whether or not to continue developing a new drug based on a cost function. The cost function takes into account both type I and type II errors in a decision making problem. It also incorporates both the cost and benefit from a drug development program. This cost-benefit approach enables company senior management to evaluate a drug program objectively and make decisions in a quantitative and rational manner. The probabilities of making correct decisions are illustrated by using a real data example.

by Eric C Yan and Ling Chen
Statistics in Medicine
September 30, 2004. Volume 23, Issue 18; page 2863
http://proquest.umi.com/pqdweb?did=794660671&sid=1&Fmt=2&clientId=13371&RQT=309&VName=PQD
http://www3.interscience.wiley.com/cgi-bin/jhome/2988

Pingbacks:

No Pingbacks for this post yet...

Search

Google
Web www.envirovaluation.org
www.costbenefitanalysis.org

Enter your Email to get updates


Powered by FeedBlitz

Non-Environmental Cost-Benefit News

Non-Environmental Cost-Benefit News.

August 2008
Sun Mon Tue Wed Thu Fri Sat
 << <   > >>
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31            
SUMMARY OF RECENT POSTS

Environmental Valuation & Cost-Benefit News

Misc

Create XML/RSS NewsFeed view this weblog as RSS !

XML Feeds

What is RSS?
Editor and Publisher: Kenneth Acks

Who's Online?

powered by
b2evolution